Well Told Grants

Grants / Department of Health and Human Services / Food and Drug Administration

RFA-FD-24-009: Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional

Closed Closed April 8, 2024 Opportunity RFA-FD-24-009

This grant is closed. A newer notice from the same program is open now: Flexible Funding Model - Advancing Domestic Mutual Reliance Through Strengthened Infrastructure Development and Maintenance for Manufactured Food Regulatory Programs (PAR-27-017). Status: Rolling or no fixed deadline. It is in our archive of Food and Drug Administration notices from 2024.

Food and Drug Administration offered grants of up to $250,000 to any type of organization. It expected to make about 2 awards worth $250,000 in total. Applications closed on April 8, 2024.

From the official notice on Grants.gov, last changed April 2, 2024. Checked November 7, 2026.

Other notices with this title

Food and Drug Administration has posted this title under other numbers: earlier or later rounds, or the same competition for another area. Each has its own dates and may change its rules.

NoticePostedDeadlineStatus
FOR-FD-24-005November 24, 2023Forecast, no dates yetForecast

Key dates

PostedJanuary 15, 2024
DeadlineApril 8, 2024
Archived by Grants.govApril 30, 2024

Who can apply

This opportunity was open to any type of organization.

All 15 applicant types the notice lists

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

What the grant funds

The purpose of this funding opportunity is to examine the utility of an in vitro simulated gastrointestinal (GI) dissolution model for the assessment of in vitro performance of amorphous solid dispersion (ASD) drug products under different clinically relevant conditions. The goal is to develop and validate the in vitro mechanistic methodology to provide an improved understanding of impact of food and acid reducing agents on the absorption for test and reference listed drug (RLD) drug products, taking into consideration their potentially different formulations and manufacturing. The bio predictive in vitro mechanistic methodology is intended to correlate the in vitro observations to in vivo outcomes, help define types of in vivo bioequivalence (BE) studies needed for ASD drug products, and inform regulatory decision-making related to mitigating the risk of potential failure modes for therapeutic equivalence for high-risk generic oral drug products.

Category: Agriculture, Consumer Protection, Food and Nutrition.

Who has won Food and Drug Administration Research grants before

From fiscal 2021 to 2025, Food and Drug Administration Research (93.103) awarded $1.2 billion across 940 grant awards, an average of $1.3 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
The Critical Path InstituteArizona13$94.0 million
National Environmental Health AssociationColorado9$55.4 million
Association of Food & Drug OfficialsPennsylvania14$50.3 million
The Medical Device Innovation ConsortiumVirginia1$48.6 million
Duke UniversityNorth Carolina11$35.6 million

Top states: Arizona ($102 million), California ($95.7 million), Pennsylvania ($83.3 million), Maryland ($80.1 million), Virginia ($79.7 million).

Applying now

This notice no longer takes applications. Apply under the newer notice, PAR-27-017, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.

Questions people ask

Is RFA-FD-24-009 still open?

No. It closed on April 8, 2024. A newer notice is open: PAR-27-017, rolling or no fixed deadline.

Who can apply for Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional?

Food and Drug Administration accepted applications from any type of organization.

What is the deadline for Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional?

Closed April 8, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

How much funding is available?

Awards of up to $250,000 each. About $250,000 in total across about 2 awards.

Who has won Food and Drug Administration Research grants before?

The largest recipients over five fiscal years were The Critical Path Institute, National Environmental Health Association, Association of Food & Drug Officials. The program made 940 awards worth $1.2 billion in that time.

Similar open grants